MDT vs PTGX · P/E 21, rev $36.36B vs rev $269.8M
Medtronic PLC (MDT) versus Protagonist Therapeutics Inc (PTGX) — a side-by-side from cached financials, not a winner call.
Medtronic PLC (MDT) is a medical devices company listed on US.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Latest reported MDT revenue for 2026-04-24 was $36.36B. Net income was $4.80B. Revenue was up 8.4% from 2025-04-25 to 2026-04-24. MDT currently screens at market cap $100.08B and trailing P/E 20.9.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
MDT currently screens at market cap $100.08B and trailing P/E 20.9. PTGX currently screens at market cap $7.25B.
Not investment advice. Open the MDT and PTGX stock pages for the full models.
Not investment advice.